|
Table S3.2 Number of hospitals contributing to the National Antimicrobial Utilisation Surveillance Program, by peer group and jurisdiction, 2014
|
| səhifə | 3/26 | | tarix | 12.02.2017 | | ölçüsü | 388,53 Kb. | | #8296 |
|
Table S3.2 Number of hospitals contributing to the National Antimicrobial Utilisation Surveillance Program, by peer group and jurisdiction, 2014
Jurisdiction
|
Principal referral
|
Specialist women’s
|
Large
public acute
|
Medium public acute
|
Small public acute
|
Private (nonpeered)
|
Total
|
New South Wales and Australian Capital Territory
|
12
|
0
|
21
|
10
|
0
|
0
|
43
|
Queensland
|
5
|
1
|
12
|
5
|
0
|
6
|
29
|
South Australia
|
2
|
0
|
4
|
4
|
3
|
6
|
19
|
Tasmania
|
1
|
0
|
2
|
1
|
0
|
1
|
5
|
Victoria
|
6
|
0
|
8
|
5
|
0
|
4
|
23
|
Western Australia
|
2
|
1
|
4
|
1
|
1
|
1
|
10
|
Australia
|
28
|
2
|
51
|
26
|
4
|
18
|
129
|
Note: Northern Territory data has not been included because of issues with the scope of the data supplied.
Source: NAUSP, 2014
Table S3.3 Total-hospital antimicrobial usage rates (defined daily doses per 1000 occupied-bed days) by antimicrobial class, 2010–14
Antimicrobial class
|
2010 (n = 53)
|
2011 (n = 61)
|
2012 (n = 79)
|
2013 (n = 114)
|
2014 (n = 129)
|
Aminoglycosides
|
50.87
|
46.50
|
44.49
|
41.52
|
38.45
|
Amphenicols
|
0.01
|
0.00
|
0.00
|
0.00
|
0.00
|
β-lactamase inhibitor combinations
|
185.15
|
186.99
|
187.57
|
186.82
|
180.70
|
β-lactamase-resistant penicillins
|
87.35
|
84.27
|
85.30
|
91.29
|
91.03
|
β-lactamase-sensitive penicillins
|
27.78
|
23.68
|
25.58
|
26.74
|
28.66
|
Carbapenems
|
19.02
|
18.27
|
18.88
|
19.49
|
17.79
|
Extended-spectrum penicillins
|
117.04
|
112.10
|
107.52
|
104.83
|
103.39
|
First-generation cephalosporins
|
139.04
|
142.48
|
132.39
|
133.66
|
130.90
|
Fluoroquinolones
|
53.37
|
51.06
|
43.53
|
42.90
|
39.21
|
Fourth-generation cephalosporins
|
6.03
|
5.49
|
5.21
|
5.24
|
5.50
|
Glycopeptides
|
31.34
|
32.05
|
29.65
|
28.95
|
26.01
|
Lincosamides
|
12.96
|
13.93
|
14.06
|
15.59
|
14.93
|
Macrolides
|
86.17
|
85.38
|
80.49
|
71.81
|
67.13
|
Monobactams
|
0.20
|
0.18
|
0.36
|
0.42
|
0.45
|
Nitrofurans
|
1.23
|
1.11
|
0.87
|
0.88
|
0.81
|
Nitroimidazoles
|
51.65
|
52.77
|
47.71
|
44.76
|
40.80
|
Other antibacterials (daptomycin + linezolid)
|
1.56
|
1.16
|
2.18
|
2.40
|
2.38
|
Other cephalosporins and penems (ceftaroline)
|
0.00
|
0.00
|
0.00
|
0.04
|
0.05
|
Polymyxins
|
0.43
|
0.58
|
0.63
|
0.81
|
0.77
|
Second-generation cephalosporins
|
5.39
|
5.83
|
5.41
|
5.55
|
5.75
|
Steroids
|
2.42
|
2.33
|
1.93
|
1.61
|
1.34
|
Streptogramins
|
0.13
|
0.42
|
0.54
|
0.51
|
0.51
|
Streptomycins
|
0.03
|
0.05
|
0.01
|
0.01
|
0.00
|
Sulfonamide–trimethoprim combinations
|
13.90
|
13.56
|
14.95
|
16.62
|
16.18
|
Tetracyclines
|
31.28
|
37.35
|
43.08
|
47.96
|
54.34
|
Third-generation cephalosporins
|
50.17
|
51.47
|
49.50
|
48.99
|
46.17
|
Trimethoprim
|
23.44
|
21.53
|
20.57
|
19.75
|
18.00
|
Total
|
1005.70
|
998.38
|
968.79
|
965.14
|
936.31
|
n = number of participating hospitals
Source: NAUSP, 2014
Dostları ilə paylaş: |
|
|
